PAPER Aoki M, Warita H, Kato M, Suzuki N

[Application of Hepatocyte Growth Factor for Amyotrophic Lateral Sclerosis].

Brain Nerve. 2019 Nov;71(11):1253-1260. PubMed: 31722311

PAPER Yamashita T, Abe K

[Edaravone: A New Treatment for ALS].

Brain Nerve. 2019 Nov;71(11):1245-1251. PubMed: 31722310

PAPER Watanabe Y

[Amyotrophic Lateral Sclerosis and Frontotemporal Dementia].

Brain Nerve. 2019 Nov;71(11):1227-1235. PubMed: 31722308

PAPER Atsuta N, Nakamura R, Hayashi N, Tohnai G, Katsuno M, Sobue G

[The Role of Patient Registry in the Care and Therapeutic Development for Patients with Amyotrophic Lateral Sclerosis: JaCALS].

Brain Nerve. 2019 Nov;71(11):1215-1225. PubMed: 31722307

PAPER Tomiyama H

[Impact of C9orf72 on Japanese Patients with Amytrophic Lateral Sclerosis (ALS)/Frontotemporal Dementia (FTD)].

Brain Nerve. 2019 Nov;71(11):1190-1208. PubMed: 31722305

PAPER Tsuboguchi S, Ishihara T, Sugai A, Yokoseki A, Onodera O

[Molecular Pathogenesis of Amyotrophic Lateral Sclerosis].

Brain Nerve. 2019 Nov;71(11):1183-1189. PubMed: 31722304

PAPER Yoshida M

[Neuropathology of Amyotrophic Lateral Sclerosis].

Brain Nerve. 2019 Nov;71(11):1152-1168. PubMed: 31722302

PAPER Narita Y

[A Brief Review on Recent Epidemiologic Literature and Risk Factors of Amyotrophic Lateral Sclerosis].

Brain Nerve. 2019 Nov;71(11):1129-1137. PubMed: 31722299

PAPER Swinnen B, Robberecht W, Van Den Bosch L

RNA toxicity in non-coding repeat expansion disorders.

EMBO J. 2019 Nov 13;:e101112. PubMed: 31721251

PAPER Zhu S, Wuolikainen A, Wu J, Öhman A, Wingsle G, Moritz T, Andersen PM, Forsgren L, Trupp M

Targeted Multiple Reaction Monitoring Analysis of CSF Identifies UCHL1 and GPNMB as Candidate Biomarkers for ALS.

J Mol Neurosci. 2019 Dec;69(4):643-657. Epub 2019 Nov 12 PubMed: 31721001

PAPER Urbi B, Broadley S, Bedlack R, Russo E, Sabet A

Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.

BMJ Open. 2019 Nov 11;9(11):e029449. PubMed: 31719072

PAPER Zhao N, Sun C, Zheng M, Liu S, Shi R

Amentoflavone suppresses Amyloid β1-42 neurotoxicity in Alzheimer's disease through the inhibition of pyroptosis.

Life Sci. 2019 Nov 10;:117043. PubMed: 31722188

PAPER Gambino CM, Sasso BL, Bivona G, Agnello L, Ciaccio M

Aging and Neuroinflammatory Disorders: New Biomarkers and Therapeutic Targets.

Curr Pharm Des. 2019 Nov 11; PubMed: 31721696

PAPER Nosheny RL, Jin C, Neuhaus J, Insel PS, Mackin RS, Weiner MW, Alzheimer’s Disease Neuroimaging Initiative investigators

Study partner-reported decline identifies cognitive decline and dementia risk.

Ann Clin Transl Neurol. 2019 Nov 13; PubMed: 31721455

PAPER Maurer V, Frank C, Porsiel JC, Zellmer S, Garnweitner G, Stosch R

Step-by-step monitoring of a magnetic and SERS-active immunosensor assembly for purification and detection of tau protein.

J Biophotonics. 2019 Nov 13;:e201960090. PubMed: 31721451